Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

18.5%

5 terminated out of 27 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed with results

Key Signals

3 with results67% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (8)
Early P 1 (1)
P 1 (3)
P 2 (10)

Trial Status

Completed10
Unknown7
Terminated5
Not Yet Recruiting3
Recruiting2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT07440290Phase 2Not Yet Recruiting

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

NCT07400094Phase 2Not Yet Recruiting

Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC

NCT00576134Phase 1Completed

The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement

NCT05406024Completed

Feasibility Study CORPPS

NCT05768178Phase 2Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

NCT01257633CompletedPrimary

Surgical Treatment of Early Stage Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance

NCT06137378Phase 2Recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

NCT06554028Phase 2Not Yet Recruiting

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

NCT06227039Not ApplicableUnknown

Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures

NCT04995120Phase 2Unknown

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

NCT02430675Not ApplicableCompletedPrimary

Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms

NCT02633540Phase 2TerminatedPrimary

Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

NCT04278638Not ApplicableUnknownPrimary

IORT in Local Advanced Laryngocarcinoma

NCT00721799Phase 2Completed

F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients

NCT00534729Not ApplicableCompletedPrimary

Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA

NCT03585075CompletedPrimary

Characterization of the Autofluorescence of Healthy and Pathological Tissues of Vocal Cords

NCT03010813Not ApplicableCompleted

A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery

NCT01216020Phase 2Terminated

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer

NCT03392220Not ApplicableUnknownPrimary

A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Neck Dissection for cN0 Supraglottic Laryngeal Cancer

NCT00965003Early Phase 1TerminatedPrimary

MRI Laryngeal Imaging With a Surface Coil

Scroll to load more

Research Network

Activity Timeline